MEDICAID. Provides relative to prior authorization of prescription drugs. (8/1/22)

1 AN ACT
2 To enact R.S. 46:153.3(C)(2), relative to Medicaid coverage for prescription drugs; to
3 provide for prescribed drugs used to treat schizophrenia and schizotypal or delusion
4 disorders; and to provide for related matters.
5 Be it enacted by the Legislature of Louisiana:
6 Section 1. R.S. 46:153.3(C)(2) is hereby enacted to read as follows:
7 §153.3. Medical vendor reimbursements; allowable restrictions; peer-based
8 prescribing and dispensing practice patterns; Medicaid
9 Pharmaceutical and Therapeutics Committee
10 *          *          *
11 C.          *          *
12 §2. The department shall not restrict by prior authorization any
13 prescription drug prescribed to an adult patient and determined by a
14 prescribing practitioner licensed by the state to be medically necessary for the
15 treatment and prevention of schizophrenia and schizotypal or delusion
16 disorders, including but not limited to first episode psychosis, if both of the
17 following conditions are met:

Coding: Words which are struck through are deletions from existing law; words in boldface type and underscored are additions.
(a) During the preceding year, the patient was prescribed and unsuccessfully treated with a fourteen-day treatment trial of the prescribed drug included on the single preferred drug list for which a claim was paid.

(b) The patient has previously been prescribed and obtained prior authorization for the nonpreferred prescribed drug.

* * *

The original instrument and the following digest, which constitutes no part of the legislative instrument, were prepared by Brandi Cannon.

DIGEST

Present law provides for prescription drug coverage in the Louisiana Medicaid program, including a preferred drug list established in conjunction with a prior approval process.

Proposed law retains present law but prohibits any restriction by prior authorization of a prescription drug prescribed to an adult patient and determined by a licensed prescriber to be medically necessary for the treatment and prevention of schizophrenia and schizotypal or delusion disorders if, during the preceding year, the patient was unsuccessfully treated with the preferred drug and the patient has previously been prescribed and obtained prior authorization for the nonpreferred drug.

Effective August 1, 2022.

(Adds R.S. 46:153.3(C)(2))

Summary of Amendments Adopted by Senate

Committee Amendments Proposed by Senate Committee on Health and Welfare to the original bill

1. Narrows the scope of the bill to drugs that treat schizophrenia and schizotypal or delusion disorders.

2. Makes technical changes.